AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30672056 — intervention group
Group type: COMPARATOR
Intervention: No Magee Equations
Number of subjects: 175
Study 30672056 — intervention group
Group type: EXPERIMENTAL
Intervention: Magee Equations and Ki67 availability
Number of subjects: 175
Study 30672056 — intervention group
Group type: COMPARATOR
Intervention: No Magee Equations and Ki67 availability
Number of subjects: 175
Study 30321007 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratified screening strategy considering family history, breast density, and genetic variants.
Number of subjects: 85000
Study 30321007 — intervention group
Group type: COMPARATOR
Intervention: Standard age-based screening programs recommended by the European Union.
Number of subjects: 85000
Study 27846839 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 100
Study 27846839 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 100
Study 27846839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 100
Study 27846839 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment
Number of subjects: 100
Study 25349017 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Care (SC)
Number of subjects: 700
Study 25349017 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 700
Study 22253323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus group-based self-regulatory skills intervention
Number of subjects: 43
Study 20962793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erectile medications (specific medications not mentioned), administered for two 3-month phases.
Number of subjects: 50
Study 17363761 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation (thought of personal strengths)
Number of subjects: 0
Study 17363761 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure attachment prime (thought of a close, caring relationship)
Number of subjects: 0
Study 17363761 — intervention group
Group type: COMPARATOR
Intervention: High Appearance-RS individuals thinking about negative aspects of their appearance
Number of subjects: 0
Study 16216977 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering drugs (thiazides, β-blockers, ACE inhibitors, angiotensin II receptor antagonists)
Number of subjects: 24644
Study 16216977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24644
Study 16216977 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering drugs (all classes)
Number of subjects: 24644
Study 11268707 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine HCl 13.9% cream
Number of subjects: 315
Study 11268707 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 315
Study 11268707 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulphate
Number of subjects: 315
Study 9834591 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous TIVA with propofol, ketamine, and vecuronium in combination with butorphanol (PKBt)
Number of subjects: 0
Study 9834591 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous TIVA with propofol, ketamine, and vecuronium in combination with buprenorphine (PKBp)
Number of subjects: 0
Study 9834591 — intervention group
Group type: COMPARATOR
Intervention: Elderly patients
Number of subjects: 0
Study 9834591 — intervention group
Group type: COMPARATOR
Intervention: Patients with long anesthetic time
Number of subjects: 0
Study 9834591 — intervention group
Group type: COMPARATOR
Intervention: Patients with general anesthesia combined with epidural anesthesia
Number of subjects: 0
Study 8006923 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 47
Study 8006923 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 47
Study 2689472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (10, 30, or 90 mg)
Number of subjects: 126
Study 2689472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (combined doses)
Number of subjects: 126
Study 2689472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 4603994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal cholera vaccine
Number of subjects: 0
Study 4603994 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous cholera vaccine
Number of subjects: 0
Study 448844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin sodium, 500 mg intramuscularly twice daily
Number of subjects: 82
Study 448844 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G procaine, 600,000 units intramuscularly twice daily
Number of subjects: 82
Study 30654479 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dietary consultations
Number of subjects: 60
Study 30654479 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo dietary supplement (fruit juice)
Number of subjects: 60
Study 30654479 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dietary consultations plus placebo fruit juice
Number of subjects: 60
Study 30654479 — intervention group
Group type: COMPARATOR
Intervention: All groups (including waitlist control)
Number of subjects: 60
Study 29190727 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program with an upper-limb prosthesis simulator
Number of subjects: 71
Study 29190727 — intervention group
Group type: COMPARATOR
Intervention: Sham training (dummy training without the prosthesis simulator)
Number of subjects: 71
Study 29190727 — intervention group
Group type: COMPARATOR
Intervention: No training at all
Number of subjects: 71
Study 25397864 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment (NIR light therapy) with a cumulative dose of 360 J
Number of subjects: 39
Study 25397864 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 39
Study 24952882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra Corega cream tasteless
Number of subjects: 40
Study 24952882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra Corega powder tasteless
Number of subjects: 40
Study 24952882 — intervention group
Group type: COMPARATOR
Intervention: Control (no denture adhesive)
Number of subjects: 40
Study 21975275 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium plus FSC (250/50 μg twice daily)
Number of subjects: 479
Study 21975275 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium plus FSC (250/50 μg twice daily) in GOLD stage II patients
Number of subjects: 479
Study 19321268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 19321268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17320747 — intervention group
Group type: EXPERIMENTAL
Intervention: Gothic arch type
Number of subjects: 63
Study 17320747 — intervention group
Group type: EXPERIMENTAL
Intervention: Height/width ratio (H/W)
Number of subjects: 63
Study 17320747 — intervention group
Group type: EXPERIMENTAL
Intervention: Romanesque arch geometry
Number of subjects: 63
Study 17320747 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (N=63)
Number of subjects: 63
Study 15341353 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanon barrier (test group)
Number of subjects: 15
Study 15341353 — intervention group
Group type: COMPARATOR
Intervention: Polylactide acetyltributyl citrate barrier (control group)
Number of subjects: 15
Study 11313504 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol using metered dose inhaler via commercial spacer device (Group 1)
Number of subjects: 60
Study 11313504 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol using metered dose inhaler via improvised spacer device (Group II)
Number of subjects: 60
Study 9492970 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat eating pattern
Number of subjects: 64500
Study 9492970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 64500
Study 9492970 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (CaD)
Number of subjects: 64500
Study 9492970 — intervention group
Group type: COMPARATOR
Intervention: Control group (women not enrolled in CT components)
Number of subjects: 64500
Study 9419773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg every 4 hours for 48 hours postpartum)
Number of subjects: 45
Study 9419773 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine curettage (immediate following delivery)
Number of subjects: 45
Study 9419773 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (intravenous magnesium sulfate 2 g/hour)
Number of subjects: 45
Study 2845461 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline infusion (mean = 14.0 micrograms/ml) in normal saline (308 mEq)
Number of subjects: 10
Study 2845461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion (350 mEq in normal saline)
Number of subjects: 10
Study 2845461 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (308 mEq)
Number of subjects: 10
Study 4206451 — intervention group
Group type: EXPERIMENTAL
Intervention: Serogroup A meningococcal polysaccharide vaccine
Number of subjects: 0
Study 4206451 — intervention group
Group type: COMPARATOR
Intervention: Tetanus toxoid (control)
Number of subjects: 0
Study 4206451 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated contrast group
Number of subjects: 0
Study 31902066 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus panitumumab
Number of subjects: 0
Study 31902066 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 0
Study 30092646 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized environmental report back
Number of subjects: 560
Study 30092646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no personalized report back)
Number of subjects: 560
Study 28429078 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching for depression
Number of subjects: 1586
Study 28429078 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone coaching)
Number of subjects: 1586
Study 26242220 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg (two 150 mg tablets) administered in fed state
Number of subjects: 60
Study 26242220 — intervention group
Group type: COMPARATOR
Intervention: Olaparib 300 mg (two 150 mg tablets) administered in fasted state
Number of subjects: 60
Study 23933029 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 12
Study 23933029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 12
Study 23933029 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12
Study 21266699 — intervention group
Group type: COMPARATOR
Intervention: Soy oil-based fat emulsion
Number of subjects: 22
Study 21266699 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based fat emulsion
Number of subjects: 22
Study 19187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with oppositional actions (E+OA)
Number of subjects: 88
Study 19187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure only (EO)
Number of subjects: 88
Study 19187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed audio‐photic stimulation (APS)
Number of subjects: 88
Study 19187817 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 88
Study 16769267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dai‐kenchu‐to (15 g/d)
Number of subjects: 17
Study 14732896 — intervention group
Group type: COMPARATOR
Intervention: Antituberculous treatment (Isoniazid, Rifampicin, Pyrazinamid, and Streptomycin) alone
Number of subjects: 32
Study 14732896 — intervention group
Group type: EXPERIMENTAL
Intervention: Antituberculous treatment plus additional pleural tapping for four weeks
Number of subjects: 32
Study 14732896 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (0.75 mg/kg body weight) tapered over four weeks (for both groups in phase II)
Number of subjects: 32
Study 14732896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function tests by spirometry (for both groups)
Number of subjects: 32
Study 14732896 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological changes (for both groups)
Number of subjects: 32
Study 10916329 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (n = 51), chewed three times daily for a minimum of five minutes each time for three months
Number of subjects: 151
Study 10916329 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol gum (placebo group, n = 50)
Number of subjects: 151
Study 10916329 — intervention group
Group type: COMPARATOR
Intervention: No gum (control group, n = 50)
Number of subjects: 151
Study 8645022 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/2 FAM (5-FU 200 mg/m2/day IV, ADM 15 mg/m2/day IV, MMC 5 mg/m2/day IV)
Number of subjects: 83
Study 8645022 — intervention group
Group type: COMPARATOR
Intervention: Control (palliative treatment alone)
Number of subjects: 83
Study 8645022 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/2 FAM
Number of subjects: 83
Study 1449142 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 4
Study 1449142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 3931363 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg glycerol trinitrate
Number of subjects: 69
Study 3931363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glycerol trinitrate)
Number of subjects: 69
Study 3931363 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg glycerol trinitrate after aortocoronary venous bypass
Number of subjects: 69
Study 29331916 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 76
Study 29331916 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study 28616088 — intervention group
Group type: EXPERIMENTAL
Intervention: Novafen administration before periodontal surgery
Number of subjects: 70
Study 28616088 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 24969635 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (7.5-22.5 mg max) followed by penile vibratory stimulation (PVS)
Number of subjects: 20
Study 24969635 — intervention group
Group type: COMPARATOR
Intervention: Sham-midodrine (placebo) followed by penile vibratory stimulation (PVS)
Number of subjects: 20
Study 23936895 — intervention group
Group type: EXPERIMENTAL
Intervention: MSN (morphine sulfate and naltrexone hydrochloride extended‐release)
Number of subjects: 0
Study 23936895 — intervention group
Group type: EXPERIMENTAL
Intervention: MS (controlled‐release morphine sulfate)
Number of subjects: 0
Study 23936895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23936895 — intervention group
Group type: EXPERIMENTAL
Intervention: MSN
Number of subjects: 0
Study 23936895 — intervention group
Group type: EXPERIMENTAL
Intervention: MS
Number of subjects: 0
Study 20484613 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 µg) administered at -60 minutes, -30 minutes, or -15 minutes
Number of subjects: 20
Study 20484613 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 µg)
Number of subjects: 20
Study 20484613 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at -30 minutes
Number of subjects: 20
Study 18160497 — intervention group
Group type: EXPERIMENTAL
Intervention: High flexion NexGen total knee replacement
Number of subjects: 56
Study 18160497 — intervention group
Group type: COMPARATOR
Intervention: Standard NexGen total knee replacement
Number of subjects: 56
Study 18160497 — intervention group
Group type: COMPARATOR
Intervention: Comparison between high flexion and standard designs
Number of subjects: 56
Study 16611394 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents-only intervention
Number of subjects: 32
Study 16611394 — intervention group
Group type: COMPARATOR
Intervention: Parents and children together intervention
Number of subjects: 32
Study 12589865 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronologically structured self‐completion questionnaire
Number of subjects: 259
Study 12589865 — intervention group
Group type: COMPARATOR
Intervention: Traditionally structured self‐completion questionnaire
Number of subjects: 259
Study 10512913 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rtPA)
Number of subjects: 0
Study 10512913 — intervention group
Group type: COMPARATOR
Intervention: heparin
Number of subjects: 0
Study 7560237 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine toothpaste
Number of subjects: 20
Study 7560237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste
Number of subjects: 20
Study 7560237 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 20
Study 1940256 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 79
Study 1940256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 79
Study 1940256 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study 7018305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium therapy for 3 months
Number of subjects: 47
Study 7018305 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 47
Study 7018305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium therapy for 3 months in depressed patients
Number of subjects: 47
Study 31500510 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP-SD (Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline)
Number of subjects: 66
Study 31500510 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 66
Study 30970436 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate/midazolam
Number of subjects: 200
Study 30970436 — intervention group
Group type: COMPARATOR
Intervention: Propofol/midazolam
Number of subjects: 200
Study 28436305 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment
Number of subjects: 500
Study 28436305 — intervention group
Group type: COMPARATOR
Intervention: Control (no intra-arterial treatment)
Number of subjects: 500
Study 24823763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 17
Study 24823763 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate (CH)
Number of subjects: 17
Study 24461317 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee polyphenols (CPPs) during glucose loading
Number of subjects: 0
Study 22962203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tier 1 Program of Project P.A.T.H.S.
Number of subjects: 216
Study 19390750 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/d cholecalciferol
Number of subjects: 218
Study 19390750 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU/d cholecalciferol
Number of subjects: 218
Study 19390750 — intervention group
Group type: COMPARATOR
Intervention: 0 IU/d cholecalciferol (placebo)
Number of subjects: 218
Study 17720256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.025% and lignocain 2%
Number of subjects: 53
Study 17720256 — intervention group
Group type: COMPARATOR
Intervention: Oxymetazoline 0.025% alone
Number of subjects: 53
Study 15228999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 128
Study 15228999 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic mesh colposuspension
Number of subjects: 128
Study 11785439 — intervention group
Group type: EXPERIMENTAL
Intervention: FemoStop device
Number of subjects: 212
Study 11785439 — intervention group
Group type: COMPARATOR
Intervention: Manual pressure
Number of subjects: 212
Study 9641433 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac PLO (2% diclofenac)
Number of subjects: 14
Study 9641433 — intervention group
Group type: COMPARATOR
Intervention: Placebo PLO (no diclofenac)
Number of subjects: 14
Study 9215651 — intervention group
Group type: EXPERIMENTAL
Intervention: SEDDS formulation (1125 mg twice daily)
Number of subjects: 49
Study 9215651 — intervention group
Group type: COMPARATOR
Intervention: Elixir (750 mg three times daily)
Number of subjects: 49
Study 9215651 — intervention group
Group type: EXPERIMENTAL
Intervention: SEDDS formulation (750 mg three times daily)
Number of subjects: 49
Study 9215651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SEDDS regimens
Number of subjects: 49
Study 9215651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 49
Study 9215651 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily administration
Number of subjects: 49
Study 1764872 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 1764872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1764872 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate and Placebo (in unknown order)
Number of subjects: 0
Study 6276278 — intervention group
Group type: EXPERIMENTAL
Intervention: New, specially prepared swelling substances administered at the recommended doses
Number of subjects: 20
Study 30583772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 188
Study 30583772 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet (Control)
Number of subjects: 188
Study 27983733 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg caffeine drink
Number of subjects: 50
Study 27983733 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 50
Study 25572345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis
Number of subjects: 122
Study 25572345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 122
Study 25572345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 23598607 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 6 months
Number of subjects: 40
Study 23598607 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (Control)
Number of subjects: 40
Study 21204677 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention involving 7 theory-based learning lessons
Number of subjects: 104
Study 21204677 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving minimal physical activity information
Number of subjects: 104